China vitamin C manufacturer fined by US court

Updated on 20 March 2013

North China Pharmaceutical has been fined $162 million for price fixing

fine-china-firm

Weisheng Pharmaceutical and China Pharmaceutical settled the case out of court by offering to pay $22.5 million

Singapore: A US court has fined North China Pharmaceutical (NCPC), a vitamin C manufacturer and antibiotics supplier, $162 million for price fixing. This is the first time that a Chinese drug company has been fined in an US anti-trust case.

Weisheng Pharmaceutical and China Pharmaceutical, also Vitamin C manufacturers from China and named in the lawsuit, have settled the case out of court by offering to pay $22.5 million. NCPC manufacturers over 430 kinds of antibiotics, semi-synthetic antibiotics, pharmaceutical intermediates, vitamins, biotechnology products, veterinary and neutraceuticals both in bulk and in finished products.

NCPC and Hebei Welcome Pharmaceutical, its Vitamin C production unit, were found guilty in a conspiracy to fix prices of Vitamin C' tablets in the US. The lawsuit were filed last month by two US companies. The NCPC reportedly said it would appeal the ruling.

Leave a Reply

Post Comment

Special Features

Survey Box

Ranbaxy Controversy

Will the Ranbaxy controversy end the Indian pharma dominion in the US market?

Send this article by email

X